Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Malignancies × tanespimycin × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Lymphoma, Mantle-Cell 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Follicular 6 Lymphoma, B-Cell, Marginal Zone 6 Unspecified Adult Solid Tumor, Protocol Specific 5 Sezary Syndrome 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Mycosis Fungoides 5 Lymphoma, T-Cell, Cutaneous 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Large-Cell, Immunoblastic 5 Burkitt Lymphoma 5 Lymphoma, Large-Cell, Anaplastic 4 Immunoblastic Lymphadenopathy 4 Hodgkin Disease 4 Waldenstrom Macroglobulinemia 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid, Accelerated Phase 3 Leukemia 3 Blast Crisis 3 Sarcoma 2 Prostatic Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Multiple Myeloma 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Myeloid, Acute 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

parsaclisib 2 cemiplimab 2 Midazolam 2 MLN 8237 2 Injections 2 tanespimycin 1 spartalizumab 1 repaglinide 1 epothilone B 1 drospirenone 1 cabiralizumab 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1 Ipilimumab 1 Gemcitabine 1 Ethinyl Estradiol 1 Drug Therapy 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00724425 2015-04-15

A Phase 1 Dose Escalation Study of IPI-493

Infinity Pharmaceuticals, Inc.

Phase 1 Terminated

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡